Halyard Health Inc (HYH) is Reiterated by Deutsche Bank to Buy, Raises Price Target to $ 41

Halyard Health Inc (HYH) was Reiterated by Deutsche Bank to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 41 from a previous price target of $36 . Deutsche Bank advised their investors in a research report released on Aug 10, 2016.

Many Wall Street Analysts have commented on Halyard Health Inc. Company shares were Reiterated by Stifel on Aug 4, 2016 to “Buy”, Firm has raised the Price Target to $ 38 from a previous price target of $37 .Company shares were Reiterated by Stifel on Jun 14, 2016 to “Buy”, Firm has raised the Price Target to $ 37 from a previous price target of $32 .

On the company’s financial health, Halyard Health Inc reported $0.45 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Aug 3, 2016. Analyst had a consensus of $0.36. The company had revenue of $400.00 million for the quarter, compared to analysts expectations of $382.39 million. The company’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Halyard Health Inc closed down -0.29 points or -0.80% at $36 with 3,24,590 shares getting traded on Monday. Post opening the session at $36.26, the shares hit an intraday low of $35.75 and an intraday high of $36.43 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Sep 8, 2015, Robert E Abernathy (CEO) purchased 10,000 shares at $31.06 per share price. According to the SEC, on Sep 2, 2015, Steven E Voskuil (CFO) purchased 1,000 shares at $30.00 per share price.

Halyard Health Inc. seeks to advance health and healthcare by preventing infection eliminating pain and speeding recovery. The Company has two business segments: Surgical and Infection Prevention (S&IP) and Medical Devices. The Company’s S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections. S&IP’s product portfolio includes sterilization wrap surgical drapes and gowns facial protection protective apparel and medical exam gloves. Medical Devices segment provides a portfolio of product offerings including post-operative pain management solutions minimally invasive interventional (or chronic) pain therapies closed airway suction systems and enteral feeding tubes focused on pain management and respiratory and digestive health.

Halyard Health Inc

Leave a Reply

Halyard Health Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Halyard Health Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.